| mRNA |
Axitinib |
CTRPv2 |
pan-cancer |
AAC |
0.0069 |
0.8 |
| mRNA |
SCH-79797 |
CTRPv2 |
pan-cancer |
AAC |
-0.0069 |
0.9 |
| mRNA |
TAE684 |
CCLE |
pan-cancer |
AAC |
0.0083 |
0.9 |
| mRNA |
XMD8-92 |
GDSC1000 |
pan-cancer |
AAC |
0.0087 |
0.9 |
| mRNA |
Rapamycin |
GDSC1000 |
pan-cancer |
AAC |
0.009 |
0.9 |
| mRNA |
FTI-277 |
GDSC1000 |
pan-cancer |
AAC |
-0.0062 |
0.9 |
| mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0062 |
0.9 |
| mRNA |
FH535 |
GDSC1000 |
pan-cancer |
AAC |
-0.0062 |
0.9 |
| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0058 |
0.9 |
| mRNA |
foretinib |
CTRPv2 |
pan-cancer |
AAC |
-0.0062 |
0.9 |